ストックスクリーナーアプリを入手
0.000001
100.00%
-0.021
Virpax Pharmaceuticals Inc (VRPX) 最新ニュース
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MyChesCo
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Virpax Pharmaceuticals Announces Positive Results from U.S. Army Study on Probudur™ - Kalkine Media
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - FinancialContent
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - FinancialContent
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
Virpax Regains Compliance with Nasdaq Minimum Bid Price | User | ricentral.com - FinancialContent
3 Penny Stocks to Watch Now, 7/23/24 - Nasdaq
Maxim Group Upgrades Virpax Pharmaceuticals (VRPX) - Nasdaq
Virpax Pharma rises as pain medication shows promise in animal study - TradingView
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™ - Business Wire
Virpax overhauls its board as a condition of $2.5M loan deal; stock price doubles - The Business Journals
Virpax Pharmaceuticals faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention - FinancialContent
Virpax Pharmaceuticals Reports Increased Losses Amid Promising Developments - MyChesCo
Virpax Announces Pricing of $2.25 Million Public Offering | User | woonsocketcall.com - FinancialContent
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments | User | woonsocketcall.com - FinancialContent
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™ - Stock Titan
Virpax Pharmaceuticals Reports 2023 Year-End Results - The AI Journal
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions - MyChesCo
Virpax Pharmaceuticals Reports 2023 Year-End Results | User | woonsocketcall.com - FinancialContent
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. - Business Wire
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement - Yahoo Finance
User - FinancialContent
Virpax Pharmaceuticals shareholders okay reverse stock split (NASDAQ:VRPX) - Seeking Alpha
Court of Chancery Finds Officer Liable for Competing With Corporation and Misappropriating Trade Secrets - Skadden, Arps, Slate, Meagher & Flom LLP
Virpax Pharmaceuticals Appoints Gerald Bruce as CEO and Dr. Eric Floyd as Chairman - citybiz
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review - FinancialContent
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research - FinancialContent
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies - FinancialContent
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):